OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2013 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 14, 2013 at 1:20 p.m. ET at the Le Parker Meridien Hotel in New York City.

A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.